SARS_CoV_2 mutation literature information.


  ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker.
 PMID: 34433803       2021       Signal transduction and targeted therapy
Method: B.1.351: D80A, D215G, A242-244 deletion, K417N, E484K, N501Y, D614G, A701V.


  Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern.
 PMID: 34430803       2021       iScience
Method: Antibody preparations were evaluated by SARS-CoV-2 pseudovirus neutralization assay (PsVNA) using WA-1 strain, UK variant (B.1.1.7 with spike mutations: H69-V70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H), SA variant (B.1.351 strain with spike mutations L18F, D80A, D215G, L242-244del, R246I, K417N, E484K, N501Y, D614G, and


  Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York.
 PMID: 34428777       2021       Nature
Introduction: B.1.526-E484K and B.1.526-S477N share the characteristic spike protein mutations L5F, T95I, D253G, D614G and either A701V or Q957R, along with either E484K or S477N.
Introduction: Isolates subsequently branched into four sub-lineages, with two major groups B.1.526-E484K and B.1.526-S477N containing A701V, and a smaller sub-lineage B.1.526-S477N containing Q957R.
Introduction: Pseudoviruses were constructed conta


  GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
 PMID: 34388530       2021       Biomedicine & pharmacotherapy
Introduction: The SARS-CoV-2 beta variant contains nine mutations in the spike protein: D614G, Delta242-Delta244, and R246I in the N-terminal domain; three mutations (K417N, E484K, and N501Y) in the RBD; and one mutation (A701V) near the furin cleavage site.


  Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York.
 PMID: 34373458       2021       Nature communications
Abstract: The most common sets of spike mutations in this lineage (now designated as B.1.526) are L5F, T95I, D253G, E484K or S477N, D614G, and A701V.
Method: Human plasma samples were assayed for neutralization activity against lentiviruses pseudotyped with SARS-CoV-2 spike containing a 21-amino acid cytoplasmic tail deletion and either D614G or mutations corresponding to lineage B.1.526 (v.1: L5F, T95I, D253G, E484K, D614G, and A701V; v.


  Phylogenomic analysis of SARS-CoV-2 from third wave clusters in Malaysia reveals dominant local lineage B.1.524 and persistent spike mutation A701V.
 PMID: 34362872       2021       Tropical biomedicine
Abstract: This lineage contains another spike mutation A701V that co-exists with the D614G spike mutation that was predominant in most of the third-wave clusters.


  Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants.
 PMID: 34351895       2021       PLoS computational biology
Result: 501.V2 includes the mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V.


  Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.
 PMID: 34312390       2021       Nature communications
Method: The B.1.351 Spike carries the mutations D80A, D215G, del242-244, K417N, E484K, N501Y, D614G, and A701V (from EPI_ISL_745109).



Browser Board

 Co-occurred Entities




   Filtrator